top of page

Team

Dedication. Expertise. Passion.

This is your Team section. It's a great place to introduce your team and talk about what makes it special, such as your culture or work philosophy. Don't be afraid to illustrate personality and character to help users connect with your team.

SPEAKERS 2022

Dr. Thierry Schlama

Dr. Thierry Schlama

Director of the Biocatalysis activities in Novartis Chemical R&D

Thierry Schlama has 24 years experience in chemical processes and innovative technologies development. He started his career in 1997 at Rhone Poulenc, developing new routes to pharmaceutical intermediates and has been instrumental in the industrialization of the Hydrolytic Kinetic Resolution technology invented by E.Jacobsen lab and Buchwald amination through strong collaboration with Harvard University and MIT. He joined Novartis in 2006 where he held different roles within Chemical R&D organization. Recipient of the Novartis Innovation Award (VIVA) award in 2017, Thierry has been instrumental in building strategic partnerships, creating innovation platforms, and leading biocatalysis implementation within CHAD organization from early to full scale manufacturing. Author of several publications, patents and book chapters, Thierry holds a PhD in Organic Chemistry from the University of Strasbourg and he’s passionate of changing the way we do organic chemistry using the power of enzymes.
Dr. Anke Arnold-Tugulu

Dr. Anke Arnold-Tugulu

Head of Regulatory Affairs at Azafaros

Dr. Anke Arnold-Tugulu has over 15 years of experience in the leadership in pharmaceutical industry. Currently she is the Head of Regulatory Affairs at Azafaros working in the area of rare lysosomal storage disorders. She has solid experience across various therapeutic areas (Immunology, anti-infectives, cardiovascular, ophthalmology, transplantation, oncology, pulmonary, haematology) and all stages of drug development, from entry into human to post marketing. She also worked with orphan drugs and rare diseases. She is also a Co-Founder of the NovoNexile AG.
Dr. Camille Peitsch

Dr. Camille Peitsch

Head Research, Development & Commercialization, InnoMedica Schweiz

Camille Peitsch joined InnoMedica in February 2017 and after a while she took over the Research and Development team. As a molecular biologist, she contributes to InnoMedica with her experience in the visualization of nanostructures and cellular transport mechanisms as well as in method development and establishment. This knowledge enabled her to explore the structural design and mode of action of InnoMedica's liposomes and to work with the team to develop further medical applications for the nanotechnology platform. Since January 2022, Camille Peitsch is a member of the management as Head of Research, Development & Commercialization. In 2012, Camille Peitsch completed her master's degree in molecular biology at the University of Basel. After that, she did her PhD at the Institute of Anatomy of the University of Bern and wrote her thesis under the guidance of Prof. Benoît Zuber under the title \"Cutting Edge Electron Microscopy for Calcium-Dependent Exocytosis and Trypanosome Morphology Studies\". During this research, she developed a method for isolating the cell periphery for cryo-electron microscopy and completed her PhD in March 2017.
Prof. Dr. Mark Rubin

Prof. Dr. Mark Rubin

Director of the Bern Center for Precision Medicine

Director of the Department for Biomedical Research (DBMR) and head of the management board. Prof Rubin was the founding director of the Englander Institute for Precision Medicine at Weill Cornell Medicine and co-leader of the All of Us program (U.S. National Precision Medicine Program) for New York City before being recruited to Bern.
Prof. Dr. Stavroula Mougiakakou

Prof. Dr. Stavroula Mougiakakou

Associate Professor, University of Bern

Stavroula Mougiakakou holds a Ph.D. degree in electrical and computer engineering from the National Technical University of Athens. She is currently leading the AI in Health and Nutrition laboratory at the ARTORG Center for Biomedical Engineering Research Bern, Switzerland. Her research interests include artificial intelligence, machine learning, computer vision and their application in prevention, diagnosis, prognosis, and treatment personalisation of acute and chronic diseases. Over the last years she successfully involved herself and her research group in many competitive national, European, and internationally funded R&D projects, resulting in numerous publications, a number of patents, and several technology transfer activities.
bottom of page